Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3905538 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL10683777 | 0.78 | — | — | |
| SCHEMBL7522331 | 0.75 | TSHR (0.33) | TSHRHSD17B10PHF8KDM2A | |
| SCHEMBL6703395 | 0.73 | — | — | |
| SCHEMBL15177751 | 0.71 | — | — | |
| SCHEMBL20220993 | 0.69 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL21765845 | 0.69 | ALDH1A1 (0.41) | TSHRHSD17B10PHF8KDM2AALDH1A1 | |
| SCHEMBL3905585 | 0.69 | — | — | |
| SCHEMBL22981787 | 0.68 | CA1 (0.38) | — | |
| SCHEMBL11704882 | 0.68 | KMT2A (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619408-A1 | THE SYNTHESIS OF OMAPATRILAT | Endothelium Scanning Nanotechnology Limited (AU) | 2025-09-24 | — | — | EP | claimed |
| WO-2024103123-A1 | THE SYNTHESIS OF OMAPATRILAT | Endothelium Scanning Nanotechnology Limited (AU) | 2024-05-23 | — | — | WO | claimed |
| CN-117860893-A | Application of disulfide reducer in preparation of medicines for treating and preventing IgA nephropathy | 深圳市陆为生物技术有限公司 | 2024-04-12 | — | — | CN | claimed |
| US-20240076553-A1 | NONIONIC, REDOX-CLEAVABLE SURFACTANT FOR MASS SPECTROMETRY-BASED PROTEOMICS AND STRUCTURAL BIOLOGICAL APPLICATIONS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2024-03-07 | — | — | US | claimed |
| EP-1532965-B1 | Cosmetic composition based on a cosmetical active ingredient and an gel comprising at least one reticulated network of reticulated polymer particles. | OREAL (FR) | 2007-08-22 | — | — | EP | claimed |
| EP-1352630-B1 | Metallic shaping process which imparts cosmetic properties similar to shampooing to keratinous fibres | OREAL (FR) | 2006-03-01 | — | — | EP | claimed |
| US-20050186165-A1 | Cosmetic composition based on a cosmetically active compound and a gel comprising at least one crosslinked network of crosslinked polymer particles | L'OREAL S.A. (FR) | 2005-08-25 | — | — | US | claimed |
| EP-1532965-A1 | Cosmetic composition comprising a cosmetical active ingredient and at least one reticulated network of reticulated polymer particles | L'OREAL (FR) | 2005-05-25 | — | — | EP | claimed |
| US-20030223944-A1 | Metallic coating process for giving keratin fibres shampoo-remanent cosmetic properties | L'OREAL (FR) | 2003-12-04 | — | — | US | claimed |
| EP-1352630-A2 | Metallic shaping process which imparts cosmetic properties similar to shampooing to keratinous fibres | L'OREAL (FR) | 2003-10-15 | — | — | EP | claimed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12522819-B2 | Systems and methods for determining nucleic acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-01-13 | — | — | US | disclosed |
| US-12522820-B2 | Systems and methods for determining nucleic acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-01-13 | — | — | US | disclosed |
| US-12473546-B2 | Systems and methods for determining nucleic acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250340573-A1 | THE SYNTHESIS OF OMAPATRILAT | ENDOTHELIUM SCANNING NANOTECHNOLOGY LTD (AU) | 2025-11-06 | — | — | US | disclosed |
| WO-1998020156-A1 | HYDROLASE BINDING ASSAY | MERCK FROSST CANADA & CO. (CA) | 1998-05-14 | — | — | WO | disclosed |
| US-5523215-A | CULTURING HOST CELL EXPRESSING DESIRED PROTEIN IN MEDIUM CONTAINING COPPER IONS, DISRUPTING, INCUBATING INSOLUBLE FRACTION WITH CHAOTROPIC AGENT TO DISSOLVE CONTAMINANTS, SEPARATING, TREATING INSOLUBLE FRACTION WITH REDUCING AGENT | CHIRON CORPORATION (US) | 1996-06-04 | — | — | US | disclosed |
| US-5378813-A | Reduction of disulfide bonds using 2,5-dimercaptotetramethyl adipamide | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0623141-A1 | SELECTION OF BINDING-MOLECULES | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014108-A1 | SELECTION OF BINDING-MOLECULES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076553-A1 | NONIONIC, REDOX-CLEAVABLE SURFACTANT FOR MASS SPECTROMETRY-BASED PROTEOMICS AND STRUCTURAL BIOLOGICAL APPLICATIONS | PTMS, SRMS, DSP | TSHR 4725/4885HSD17B10 1836/4885PHF8 3937/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | TSHR 431/4885HSD17B10 4252/4885PHF8 3725/4885 |
| US-20250340573-A1 | THE SYNTHESIS OF OMAPATRILAT | PARP1, PDE7A, TBXAS1 | TSHR 3809/4885HSD17B10 2422/4885PHF8 2822/4885 |
| US-20050186165-A1 | Cosmetic composition based on a cosmetically active compound and a gel comprising at least one crosslinked network of crosslinked polymer particles | CUTA, SUCLG1, KAT7 | TSHR 3342/4885HSD17B10 694/4885PHF8 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.